<DOC>
	<DOCNO>NCT02865668</DOCNO>
	<brief_summary>The purpose study evaluate bioequivalence metformin component Fixed Dose Combination ( FDC ) tablet compare metformin Extended Release ( XR ) tablet coadministered canagliflozin healthy feed fasted participant .</brief_summary>
	<brief_title>A Study Assess Bioequivalence Metformin Component Fixed Dose Combination Tablet Canagliflozin Metformin Extended Release With Respect Metformin XR Tablet Coadministered With Canagliflozin Healthy Fed Fasted Participants</brief_title>
	<detailed_description />
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Canagliflozin</mesh_term>
	<criteria>Contraceptive use men woman consistent local regulation regard use contraceptive method participant participate clinical study Before randomization , woman must either Not childbearing potential childbearing potential agrees use highly effective method contraception ( failure rate less [ &lt; ] 1 percent [ % ] per year use consistently correctly ) throughout study All woman must negative urine pregnancy test Screening Day 1 Treatment Period Body mass index ( BMI ) ( weight [ kg ] /height^2 [ ] 2 ) 18 30 kg/m^2 ( inclusive ) , body weight less 50 kilogram ( kg ) Blood pressure 90 140 millimeter mercury ( mmHg ) , inclusive , systolic high 90 mmHg diastolic Screening Day 1 Treatment Period Normal renal function evidence estimate glomerular filtration rate ( eGFR ) &gt; =90 milliliter per minute ( mL/min ) /1.73m2 use Modification Diet Renal Disease Study ( MDRD ) equation define protocol History current clinically significant medical illness include ( limited ) cardiac arrhythmia cardiac disease , hematologic disease , coagulation disorder ( include abnormal bleeding blood dyscrasia ) , lipid abnormality , significant pulmonary disease , include bronchospastic respiratory disease , diabetes mellitus , renal hepatic insufficiency , thyroid disease , neurologic psychiatric disease , infection , illness investigator considers exclude participant could interfere interpretation study result Clinically significant abnormal value hematology , clinical chemistry , urinalysis assess investigator Screening Day 1 first Treatment Period Clinically significant abnormal physical examination , vital sign , 12 lead electrocardiogram ( ECG ) ( Screening ) assess investigator Screening Day 1 first Treatment Period deem appropriate investigator Use prescription nonprescription medication ( include vitamin herbal supplement ) , except acetaminophen , hormonal contraceptive hormonal replacement therapy within 14 day first dose study drug schedule History , reason believe participant history drug alcohol abuse within past 5 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>